TORONTO, Jan. 18, 2013 /CNW/ – On January 17, 2013, law firm ROCHON | GENOVA filed its certification record in a proposed class action on behalf of users of a diabetes drug ACTOS (pioglitazone hydrochloride) against Takeda Pharmaceutical and Eli Lilly. The action alleges that the defendants knew or ought to have known that ACTOS materially increases the risks of bladder cancer and failed to disclose those risks in a timely manner and have failed to recall the drug in Canada.
The case is brought by the daughter of a Toronto woman who died in April 2011 after battling bladder cancer for more than two years following her use of ACTOS. Her daughter, a registered nurse, is confident in the strength of the evidence in support of the case: “I believe the expert evidence that’s been filed confirms what manufacturers knew all along about the association between ACTOS and bladder cancer. They had this information and it should have been shared with doctors and patients years ago. There were much safer treatments my mother could have used to control her diabetes without putting her life at risk; she should have been given all the relevant information to make an informed choice about her treatment. That choice was taken away from her.”
The allegations raised in the claim have not yet been proven in court. The plaintiff and class members are represented by the Toronto based law firm of ROCHON | GENOVA .
For further information: ROCHON | GENOVA 121 Richmond St. W, Suite 900 Toronto, Ontario M5H 2K1 Telephone: 416-363-1867 or toll-free: 1-866-881-2292 Website address: www.rochongenova.com .
